AstraZeneca (LON:AZN)

AstraZeneca (LON:AZN)


Share Price
6,215.00 p
Change
21 (0.34 %)
Market Cap
£81,526.93 m
Proactive Investors - Run By Investors For Investors

AstraZeneca RNS Release

Director/PDMR Shareholding


RNS Number : 3963Y
AstraZeneca PLC
08 May 2019
 

8 May 2019 14:00 BST

 

 

TRANSACTION BY PERSON DISCHARGING MANAGERIAL RESPONSIBILITIES

Disclosure under Article 19 of the EU Market Abuse Regulation

 

AstraZeneca PLC (the Company) announces that, on 7 May 2019, it was notified by Marc Dunoyer, the Chief Financial Officer of the Company, that, on 7 May 2019, Mr Dunoyer purchased 8,500 Ordinary Shares of $0.25 each in the Company (Shares) at a price of £58.00 per Share.

 

The attached notification, made in accordance with the requirements of the EU Market Abuse Regulation, give further detail.

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Marc Dunoyer

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Chief Financial Officer

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

AstraZeneca PLC

b)

 

LEI

 

 

PY6ZZQWO2IZFZC3IOL08

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

 

Ordinary Shares of US$0.25 each in AstraZeneca PLC

 

 

GB0009895292

 

b)

 

Nature of the transaction

 

 

Share purchase

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

 

Volume(s)

GB£58.00

8,500

 

 

d)

 

Aggregated information

 

 

- Aggregated volume

 

 

- Price

 

 

Not applicable - single transaction

 

e)

 

Date of the transaction

 

 

7 May 2019

f)

 

Place of the transaction

 

 

XLON

 

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit astrazeneca.com and follow us on Twitter @AstraZeneca.

 

Media Relations



Gonzalo Viña


+44 203 749 5916

Rob Skelding

Oncology

+44 203 749 5821

Rebecca Einhorn

Oncology

+1 301 518 4122

Matt Kent

BioPharma

+44 203 749 5906

Jennifer Hursit

Other

+44 203 749 5762

Christina Malmberg Hägerstrand

Sweden

+46 8 552 53 106

Michele Meixell

US

+1 302 885 2677





Investor Relations



Thomas Kudsk Larsen


+44 203 749 5712

Henry Wheeler

Oncology

+44 203 749 5797

Christer Gruvris

BioPharma (cardiovascular; metabolism)

+44 203 749 5711

Nick Stone

BioPharma (respiratory, renal)

+44 203 749 5716

Josie Afolabi

Other medicines

+44 203 749 5631

Craig Marks

Finance, fixed income

+44 7881 615 764

Jennifer Kretzmann

Corporate access, retail investors

+44 203 749 5824

US toll-free


+1 866 381 72 77

 

Adrian Kemp

Company Secretary

AstraZeneca PLC

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHUWVARKAAVRAR

AstraZeneca Timeline

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use